The company, which supplies medicines and medical products, has a share of Russian capital, and its frozen assets cannot be transferred for management due to bureaucratic delays

LLC "Venta.LTD", one of the leaders in the Ukrainian pharmaceutical market, holds about 15% of the market and collaborates with major international manufacturers such as Bayer, Pfizer, KRKA, "Darnitsa," and "Farmak." However, 24% of its assets belong to Russian owners. As of June 2024, the frozen share of the company was estimated at approximately UAH 90 million.

The story of transferring these assets for management has been ongoing for over three years. Initially, the competition was announced for over a year, but the process was delayed due to issues with the tender documentation. When the competition finally took place, it turned out that the chosen manager was connected to the company's owner. The final barrier was the lack of a decision from the Antimonopoly Committee regarding concentration, which has been pending for almost four months.

To address such situations, the ARMA reform (Law 4503-IX) provides for a new procedure for selecting managers, which will prevent the involvement of related parties and help avoid such "suspended" situations in the future.

For more details on what is happening with the frozen Russian capital in "Venta.LTD," read our research via the link.